WeVote
Log In

Bill

Bill

HB 6132

AN ACT REQUIRING HEALTH INSURANCE COVERAGE FOR ALLERGEN INTRODUCTION DIETARY SUPPLEMENTS FOR INFANTS.

2025 Regular Session Introduced by Robin Comey and 1 co-sponsor

Connecticut would require health insurers to cover allergen introduction dietary supplements for infants to potentially reduce food allergy development.

REF. TO JOINT COMM. ON Insurance and Real Estate
#allergies #dietarysupplements #healthinsurance
0
WeVote Research Nonpartisan
Bill Summary · HB 6132

Legislative bill overview

HB 6132 would mandate that health insurance plans in Connecticut cover allergen introduction dietary supplements for infants. The bill requires insurers to include these products in their coverage without specifying cost-sharing requirements or age parameters beyond "infants." This represents a novel insurance coverage mandate focused on preventive allergy exposure products.

Why is this important

Early allergen introduction has emerged from recent research (like the LEAP study) suggesting it may reduce the risk of food allergies in children, making this a potential public health intervention. However, mandating insurance coverage for specific dietary supplements raises questions about which products qualify, evidence standards, and cost implications for insurers and policyholders. The bill also reflects a broader trend of using insurance mandates to promote specific health practices.

Potential points of contention

  • Product definition and oversight: The bill doesn't clarify which allergen introduction products qualify, raising concerns about whether this covers only evidence-based formulations or any marketed supplement, and who determines medical necessity
  • Cost and coverage scope: Mandated benefits typically increase insurance premiums; the bill doesn't specify coverage limits, copayments, or maximum reimbursement amounts, potentially creating open-ended insurer liability
  • Clinical evidence gaps: While promising, allergen introduction research is still evolving, and mandating coverage before clinical guidelines solidify could fund products of uncertain efficacy or safety profiles

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.